{{Rsnum
|rsid=1110866
|Gene=ARHGEF3
|Chromosome=3
|position=56792296
|Orientation=plus
|GMAF=0.3476
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=ARHGEF3
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 47.7 | 35.4 | 16.9
| HCB | 22.7 | 45.5 | 31.8
| JPT | 22.2 | 51.1 | 26.7
| YRI | 87.1 | 12.9 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 22.7 | 45.5 | 31.8
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1110866
|Name_s=
|Gene_s=ARHGEF3
|Feature=
|Evidence=PubMed ID:18499081
|Annotation=In family-based association tests of women from Australia and the UK, rs1110866 was one of five SNPs that demonstrated significant association with decreased age-adjusted bone mineral density.
|Drugs=
|Drug Classes=
|Diseases=Osteoporosis
|Curation Level=Curated
|PharmGKB Accession ID=PA161748317
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1110866
|overall_frequency_n=41
|overall_frequency_d=128
|overall_frequency=0.320312
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=33
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}